VINGMED AS

Org. no. 848236632 · ASKER · Founded 1987 · 90 employees

Score · fiscal year 2025

60of 100

How to read this: the company is ahead of 72 % of medium-sized companies in the same sector in 2025. What does this mean?

Rank: 9,075 of 30,442 · Handel

Profile

Cheetah · Sprinter

High profitability, lower solidity

Position against comparable companies in 2025, not a verdict on the company. Based on profitability 91 and solidity 35 out of 100 among medium-sized companies in the same sector in 2025. Methodology

Against the sector

VINGMED AS is 10 points above the median for medium-sized companies in the same sector in 2025.

Median score 50 among 1,664 companies.

Against medium-sized companies in the same sector in 2025: operating margin 12.1% (median 3.1%) and equity ratio 25.1% (median 32.6%).

Source: Register of Company Accounts and Central Coordinating RegisterFetched 26 October 2026Report an issue
Key figures · 2025

The numbers behind the score

The numbers behind the score · 2025
MeasureCompanyMedianAhead of
Operating revenue640 MNOK176 MNOK
Operating margin 12.1% 3.1% 92 %
Profit margin 12.2% 3.1% shown, not part of the index
Return on assets 30.1% 11.3% 89 %
Equity ratio 25.1% 32.6% 36 %
Debt-to-equity 2.98 2.02 35 %
Current ratio 1.19 1.38 33 %
Revenue growth 16.4% 6.7% 74 %
Revenue per employee7.11 MNOK6.44 MNOK

The median and “ahead of” refer to medium-sized companies in the same sector in 2025. The bar shows the share of companies the figure is ahead of.

With an index of 60, VINGMED AS does better than 72% of medium-sized companies in the same sector (1,668 companies) in 2025.

Over time

Score 2023–2025

CompanyMedian0255075100202320242025
  • VINGMED AS
  • Median: medium-sized companies in the same sector
Summary analysis

VINGMED AS has a score of 60 for 2025, rank 9,075 of 30,442 in the sector.

Strongest: Profitability: percentile 91 against peers, operating margin 12.1% against a median of 3.1%. Growth: percentile 74 against peers, revenue growth 16.4% against a median of 6.7%.

Weakest: Liquidity: percentile 33 against peers, current ratio 1.19 against a median of 1.38. Solidity: percentile 35 against peers, equity ratio 25.1% against a median of 32.6%.

Worth a closer look

Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made

Analysis · 2025

What the numbers say

VINGMED AS had an operating margin of 12.1% and an equity ratio of 25.1% in 2025, and ranks 9,075 of 30,442 in Handel.

From 2024 to 2025: revenue grew by 16%.

This text is generated automatically from the 2025 accounts.

Estimated value · 2025

Three simple methods

The methods give between 65 MNOK and 657 MNOK.

MethodInputMultipleEstimate
P/E Net profit: 61.1 MNOK 10.0 611 MNOK
EV/EBIT Operating profit: 77.6 MNOK
minus net debt −35.8 MNOK
8.0 657 MNOK
P/B Equity: 65.3 MNOK 1.0 65 MNOK

A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation

Indications · 2025

Worth a closer look

No rules were triggered for this year.

Indications based on the latest annual accounts from open data. Not investment or financial advice.

Data quality

No anomalies found in the figures.

Stress test · 2017

Scenario analysis: the sector's weakest year

We have no accounts for 2017, the sector's weakest year, for this company.

The sector's weakest year was 2017, with a median operating margin of −134.9%. Based on the 10 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology

Components · 2025

What the score is made of

Profitability91 weight 30%
Solidity35 weight 25%
Liquidity33 weight 15%
Growth74 weight 15%
Consistency52 weight 15%

Durability: 57 (average over 3 years)

Index version 2. Data completeness 100%: the share of the weights that had data.

2025

Questions and answers

How profitable is VINGMED AS?

The operating margin was 12.1% in 2025, against a median of 3.1% among medium-sized companies in the same sector. Return on assets was 30.1%.

How solid is VINGMED AS?

The equity ratio was 25.1% in 2025 (median 32.6%). Debt-to-equity was 2.98 (median 2.02).

What is the liquidity of VINGMED AS like?

The current ratio was 1.19 in 2025 (median 1.38).

How does VINGMED AS compare in Handel?

VINGMED AS ranks 9,075 of 30,442 in Handel for 2025. Among companies of the same size (medium-sized companies) it ranks 470 of 1,668. Revenue changed by 16.4% from the year before.

Group accounts

The company is registered as part of a group, but we have no group accounts for it. Group accounts are filed by the parent company, and open data does not say which company that is.

Read the figures with care: a company in a group can look strong because of group contributions, or weak because dividends go up to the parent. The figures are indications, not the full picture.

We do not show the group structure, because open data does not say who owns whom.

Public contracts

Contracts awarded since 2024
14
Total awarded value since 2024
3.5 MNOK
12 contracts without a stated value are not in the total.
Framework agreements
1
Left out of the total: the value is a ceiling, not actual spend.
DateBuyerNotice ValueCPV
29 June 2026 SYKEHUSINNKJØP HF Kolposkop til Helse Stavanger HF og Helse Førde HF 3.5 MNOK 33100000
12 February 2026 SYKEHUSINNKJØP HF Biopsi, nåleførere, merketråd, markører og ultralydgele til sykehusene i Helse Vest 28.0 MNOK (framework) 33141000
25 November 2025 Stange kommune 25/504 Anskaffelse av elektronisk legemiddelsystem (ELS) - Kontraktstildeling value not stated 48100000
5 September 2025 SYKEHUSINNKJØP HF Kunngjøring av kontraktstildeling - Pasientovervåkning til Sykehuset Østfold HF value not stated 33195000
8 July 2025 SYKEHUSINNKJØP HF Hemodialysebehandling utstyr og maskiner til helseforetakene i Norge value not stated 33600000
11 June 2025 SYKEHUSINNKJØP HF Kontraktstildeling: Respirasjon-overvåkning og generell oksygenbehandlling for foretakene i Helse Vest value not stated 33140000
5 February 2025 SYKEHUSINNKJØP HF Prosedyrepakker til radiologi og kardiologi til helseforetak i Helse Vest value not stated 33141600
31 January 2025 SYKEHUSINNKJØP HF Lån av vakuumbiopsisystemer og rammeavtale på tilhørende forbruksmateriell til Helse Bergen og Helse Stavanger value not stated 33100000
16 December 2024 SYKEHUSINNKJØP HF Kontraktstildeling: Endoskopiske produkter til helseforetakene i Helse Sør-Øst, Helse-Midt Norge og Helse Nord (NY) value not stated 33140000
23 August 2024 SYKEHUSINNKJØP HF Kontraktstildeling: Forbruksmateriell til EEG, ENG, EMG og ECT til foretakene i Helse Vest value not stated 33140000

Based on notices in Doffin. Does not show call-offs under framework agreements or purchases below the publication threshold. Values are as stated by the buyer.

Source: Doffin (DFØ), fetched 28 October 2026. Winners are matched on organisation number.

Contains data under the Norwegian licence for public data (NLOD 2.0) made available by Doffin/the Norwegian Agency for Public and Financial Management (DFØ). NLOD 2.0

From the Central Coordinating Register

Org. no.
848236632
Legal form
AS · part of a group
Sector
Handel (46.460)
Size tier
medium
Employees
90 registered 10 October 2026
Founded
14 December 1987 38 years in operation
Share capital
3.00 MNOK
Business address
Solbråveien 13, 1383 ASKER
Municipality
Asker rank 2 of 11 in KOSTRA group 12
Latest accounts filed
2025
Website
www.vingmed-as.no

Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre

Ownership and roles

Chief executive
Tor Kåre Havnes
Chair of the board
Kolbjørn Haarr
Board member
Ane Lene Hellevik Asheim
Board member
Tor Kåre Havnes
Auditor
CEDRA NORGE AS

Source: Central Coordinating Register, fetched 25 October 2026. Only names are shown.

Owners and shareholdings will appear here once the shareholder data extract is in place.

Coming · not built yet

Error in the data?

Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.

Report an issue

Figures last fetched 26 October 2026.

Details

Year by year · 2023–2025

Key figure202320242025Trend
Index565360
Rank10,33512,4959,075
Operating margin9.8%10.3%12.1%
Return on assets26.7%25.8%30.1%
Equity ratio25.7%25.7%25.1%
Current ratio1.231.191.19
Revenue growth–0.8%16.4%

Accounts

From the Brønnøysund Register Centre, in the company's reporting currency (NOK).

Key figure202320242025
Operating revenue545.0 MNOK549.6 MNOK639.6 MNOK
Operating profit53.6 MNOK56.4 MNOK77.6 MNOK
Profit before tax55.5 MNOK54.9 MNOK78.3 MNOK
Net profit43.3 MNOK42.8 MNOK61.1 MNOK
Financial expenses1.1 MNOK2.6 MNOK–
Total assets211.6 MNOK222.8 MNOK260.1 MNOK
Current assets194.0 MNOK196.6 MNOK230.9 MNOK
Equity54.3 MNOK57.3 MNOK65.3 MNOK
Retained earnings39.8 MNOK42.8 MNOK50.8 MNOK
Total liabilities157.3 MNOK165.5 MNOK194.8 MNOK
Current liabilities157.3 MNOK165.5 MNOK194.8 MNOK

Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 26 October 2026, accounts id 6754216.